Pricing Log in Create free account
Friday 6 November 2026 Export LQDA’s income statement to Excel — free account

Liquidia Corporation

LQDA Healthcare Drug Manufacturers Specialty & Generic

Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.

Revenue
+1,842.7%
EPS
+271.4%
Free cash flow
+270.2%
Total debt
−9.04%

Quarter to June 2026, against a year earlier

44.69 2.69 −5.68%
Market cap
$4.0B
P/E
28.5×
Fwd P/E
22.1×
Dividend yield
—
F-score
5/9
Altman Z
4.08
Beneish M
6.79
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Liquidia Corporation (LQDA) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Liquidia Corporation (LQDA) trades at a EV/Sales of 8.6×. Over the past ten years it has ranged from 1.9× (July 2018) to 130× (September 2025); the current reading is higher than 23% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.9× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 18.8× (69.57%)
FY2024 61.6× 51.40%
FY2023 40.7× 116.83%
FY2022 18.8× 15.04%
FY2022 16.3× 6.83%
FY2021 15.3× 186.72%
FY2021 5.3× 3.34%
FY2020 5.2× 19.61%
FY2020 4.3× 5.51%
FY2019 4.1× (90.59%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 15.5× 36.08%
Mar 2026 11.4× (39.35%)
Dec 2025 18.8× (35.05%)
Sep 2025 28.9× (48.66%)
25 more quarters

Against its own ten years

Low 1.9× High 130×
Ten-year median 20.0×
Current reading's percentile 23

EV/Sales against peers

Company EV/Sales
HCM HUTCHMED (China) Limited Sponsored ADR compare −0.1×
RGC Regencell Bioscience Holdings Limited compare n/m
HIMS Hims & Hers Health, Inc. compare 2.4×
SUPN Indivior Pharmaceuticals Inc. compare 2.9×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 3.0×
PBH Prestige Consumer Healthcare Inc. compare 3.5×
LNTH Lantheus Holdings, Inc. compare 4.1×
LQDA Liquidia Corporation 8.6×
AMLX Amylyx Pharmaceuticals, Inc. compare 32.5×
Drug Manufacturers Specialty & Generic industry median 2.9×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on LQDA